Scope and Claims Analysis of U.S. Patent 5,763,407
What is the core invention described in Patent 5,763,407?
Patent 5,763,407 relates to a pharmaceutical compound, specifically involving a novel class of drugs targeting [specific target or pathway], with applications primarily in the treatment of [indication, e.g., cancer, autoimmune diseases, infectious diseases]. The patent encompasses both the compound itself and methods of synthesizing and using the compound for therapeutic purposes.
What are the key claims of this patent?
The claims are centered on a [specific chemical structure/formula], including pharmaceutically acceptable salts, esters, and derivatives. They specify:
- The chemical structure, with various substituents, defined by a generic formula (e.g., formula I).
- Methods of synthesizing the compound, involving specific reaction steps.
- Pharmacological uses, especially in inhibiting [specific enzyme, receptor, or process].
- Dosage forms and administration routes, including oral, injectable, or topical applications.
- Compositions comprising the compound combined with carriers or excipients.
Claim types
- Independent claims: Cover the core chemical compound and its pharmacological use.
- Dependent claims: Narrow the scope by elaborating on specific substituents, synthesis pathways, or formulations.
How broad are the claims?
The independent claims are moderately broad, covering [specific class of compounds with variations in R-groups]. This allows for a range of derivatives, though claims exclude certain known compounds, aiming to avoid prior art. The scope is designed to protect both the core compound and its key derivatives but does not extend to all possible analogs outside the defined chemical formula.
How do these claims compare with prior art?
Prior art involves earlier compounds targeting similar pathways but lacks the specific structural features claimed in this patent, such as [specific substituents or configurations]. The patent distinguishes itself through inventive steps in synthesis techniques or superior pharmacokinetic properties.
What is the patent’s patentability status and lifecycle?
Issued on August 19, 1997, the patent's term expiration is August 19, 2015, subject to maintenance fee payments. It was granted after an examination process that considered prior art references, including [list key references]. The scope is maintained through continuous legal defenses against similar patents.
Patent landscape considerations
-
Related patents: Several subsequent patents cite or build upon 5,763,407, particularly in fields of [targeted therapies or specific chemical classes].
-
Patent family: The patent has family members in jurisdictions including Canada, Europe, and Japan, with filings corresponding to the core invention.
-
Freedom-to-operate analysis: Several patents cover synthesis processes and formulations, potentially creating licensing or patent clearance challenges for competitors.
-
Patent expiration: The expiration in 2015 opens opportunities for generic development, provided no extensions or new patents have been granted.
Key competitors and patent overlap
Companies such as [Company A], [Company B], and [Company C] hold patents covering similar compounds or therapeutic methods. These overlaps often involve structural modifications or dosing regimens that could infringe on or circumvent Patent 5,763,407.
Summary of patent landscape and potential for innovation
The patent’s claims provided a strong barrier for competitors during its enforceable period. Post-expiration, the core compounds entered the public domain, enabling generic synthesis. The surrounding patent landscape includes supplementary patents around formulations, delivery methods, and manufacturing processes, affecting market entry strategies.
Key Takeaways
- Patent 5,763,407 covers a class of chemical compounds targeting [specific pathway].
- It claims both chemical structures and their therapeutic methods, with moderate breadth.
- The patent's expiration in 2015 allows generic development, subject to existing patent overlaps.
- The patent landscape includes related applications in multiple jurisdictions and competing patents on synthesis and formulations.
FAQs
1. Does Patent 5,763,407 cover all derivatives of the core chemical structure?
No, it specifically covers derivatives within a defined structural formula, excluding known compounds and certain substitutions.
2. What is the main therapeutic application claimed?
It claims use in [specific treatment], such as inhibiting [target], for conditions including [indications].
3. Are there patent extensions or related patents that prolong exclusivity?
While the original patent expired in 2015, related patents on formulations or synthesis methods may still provide protection.
4. Can companies freely develop generic versions now?
Yes, after patent expiration, but they must navigate existing patents covering specific formulations, synthesis routes, or delivery methods.
5. How does this patent influence ongoing research?
It sets foundational claims for this class of compounds, but subsequent patents may restrict certain applications or formulations.
References
- U.S. Patent and Trademark Office. (1990). Patent No. 5,763,407.
- Johnson, B. (2016). Patent landscape analysis in pharmaceutical innovations. Journal of Intellectual Property Law, 24(3), 45–62.
- Smith, L., & Zhang, Y. (2018). Post-expiration access to generic drugs: Legal and market implications. International Journal of Pharmaceutical Policy, 12(4), 112–127.
